Processa Pharmaceuticals, Inc. (PCSA)
1.78
-0.03
(-1.66%)
USD |
NASDAQ |
Oct 26, 16:00
1.78
0.00 (0.00%)
After-Hours: 17:28
Processa Pharmaceuticals Enterprise Value : 4.860M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 4.860M |
| October 22, 2026 | 4.999M |
| October 21, 2026 | 4.720M |
| October 20, 2026 | 4.804M |
| October 19, 2026 | 4.636M |
| October 16, 2026 | 4.524M |
| October 15, 2026 | 4.497M |
| October 14, 2026 | 4.315M |
| October 13, 2026 | 4.748M |
| October 12, 2026 | 5.111M |
| October 09, 2026 | 4.050M |
| October 08, 2026 | 3.575M |
| October 07, 2026 | 3.770M |
| October 06, 2026 | 4.050M |
| October 05, 2026 | 3.966M |
| October 02, 2026 | 4.301M |
| October 01, 2026 | 4.329M |
| September 30, 2026 | 4.385M |
| September 29, 2026 | 4.720M |
| September 28, 2026 | 4.944M |
| September 25, 2026 | 4.944M |
| September 24, 2026 | 4.972M |
| September 23, 2026 | 5.083M |
| September 22, 2026 | 5.055M |
| September 21, 2026 | 4.944M |
| Date | Value |
|---|---|
| September 18, 2026 | 5.279M |
| September 17, 2026 | 5.111M |
| September 16, 2026 | 4.972M |
| September 15, 2026 | 5.270M |
| September 14, 2026 | 5.055M |
| September 11, 2026 | 5.614M |
| September 10, 2026 | 4.972M |
| September 09, 2026 | 5.363M |
| September 08, 2026 | 5.837M |
| September 04, 2026 | 5.558M |
| September 03, 2026 | 5.530M |
| September 02, 2026 | 5.670M |
| September 01, 2026 | 5.530M |
| August 31, 2026 | 5.530M |
| August 28, 2026 | 5.558M |
| August 27, 2026 | 5.698M |
| August 26, 2026 | 5.754M |
| August 25, 2026 | 5.893M |
| August 24, 2026 | 5.865M |
| August 21, 2026 | 5.614M |
| August 20, 2026 | 5.796M |
| August 19, 2026 | 5.810M |
| August 18, 2026 | 5.670M |
| August 17, 2026 | 5.754M |
| August 14, 2026 | 6.592M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.266M |
| Total Expenses (Quarterly) | 3.266M |
| EPS Diluted (Quarterly) | -1.187 |
| Earnings Yield | -314.0% |
| Normalized Earnings Yield | -306.58 |